Over the last decade, oncology drug development has been marred by the high attrition rates of new anticancer agents. These failure rates are attributed to the poor translatability of preclinical models and their suboptimal use in drug development. In this brand new report, we provide an overview of traditional 2D and 3D cell models and discuss why organoids are becoming the key tool for cancer drug development.
Traditionally, 2D cell culture models have been used to analyze and understand disease mechanisms and have provided significant contributions to our current knowledge of cancer biology. Nevertheless, 2D in vitro models are known to poorly predict patient responses to drugs.
As a result, patient-derived models, such as primary cells and patient-derived xenografts (PDX), have increasingly been adopted to evaluate drug response. These are known to more faithfully recapitulate the original tumor pathophysiology. But these models also come with their own challenges, including limited availability of patient tissue, long timelines, and high costs to develop.
As the next step up from traditional 3D models, organoids represent a revolutionary approach to drug development. They offer high in vitro predictivity of patient response, faster development timelines than in vivo models, and enhanced robustness and reproducibility compared to standard 3D in vitro systems.
The post Report: Are Tumor Organoids the Future of Cancer Drug Development? appeared first on Labiotech.eu.
Published on Tue, 01 Dec 2020 15:19:08 +0000 with keywords power automate array contains variable